Replies to post #173432 on Biotech Values

[caravon]

From the slides today, 40.3% of patients on xtandi went on a subsequent therapy versus 70.3% on the placebo arm. Specifically, 32.8% on the xtandi arm and 56.7% on the placebo arm received subsequent docetaxel.

There are obvious imbalances of chemo receiving pts in the trial arms. Close to a half of pts getting Xtandi got chemo comparing to a the placebo-arm.
Consequently, the MDVN claim that Xtandi postponed the chemo by 17 months is outright misleading.

Each time a company introduces a new "benefit parameter", one must think about another dishonest marketig gimmick.